Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF

Pharmaceutical Business Review

Jascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects to be approved for these uses.

pharminent May 18, 2026 (Last updated: May 18, 2026)

Pharmaceutical Business Review

Jascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects to be approved for these uses.

Related Stories